- Home
- NRIX vs RERE Comparison
NRIX vs RERE Comparison
Compare NRIX & RERE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- RERE
- Stock Information
- Founded
- NRIX 2009
- RERE 2011
- Country
- NRIX United States
- RERE China
- Employees
- NRIX N/A
- RERE N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- RERE Other Specialty Stores
- Sector
- NRIX Health Care
- RERE Consumer Discretionary
- Exchange
- NRIX Nasdaq
- RERE Nasdaq
- Market Cap
- NRIX 750.4M
- RERE 859.3M
- IPO Year
- NRIX 2020
- RERE 2021
- Fundamental
- Price
- NRIX $12.83
- RERE $4.10
- Analyst Decision
- NRIX Strong Buy
- RERE
- Analyst Count
- NRIX 14
- RERE 0
- Target Price
- NRIX $26.29
- RERE N/A
- AVG Volume (30 Days)
- NRIX 2.0M
- RERE 1.3M
- Earning Date
- NRIX 10-09-2025
- RERE 11-20-2025
- Dividend Yield
- NRIX N/A
- RERE N/A
- EPS Growth
- NRIX N/A
- RERE N/A
- EPS
- NRIX N/A
- RERE 0.12
- Revenue
- NRIX $83,687,000.00
- RERE $2,588,775,650.00
- Revenue This Year
- NRIX $58.48
- RERE $30.66
- Revenue Next Year
- NRIX N/A
- RERE $25.12
- P/E Ratio
- NRIX N/A
- RERE $33.73
- Revenue Growth
- NRIX 48.32
- RERE 27.39
- 52 Week Low
- NRIX $8.18
- RERE $2.00
- 52 Week High
- NRIX $27.53
- RERE $4.93
- Technical
- Relative Strength Index (RSI)
- NRIX 61.69
- RERE 52.62
- Support Level
- NRIX $12.01
- RERE $3.84
- Resistance Level
- NRIX $13.03
- RERE $4.38
- Average True Range (ATR)
- NRIX 0.86
- RERE 0.19
- MACD
- NRIX -0.03
- RERE 0.04
- Stochastic Oscillator
- NRIX 77.21
- RERE 62.50
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.